Latest TBVI Stories

Phase IIb Proof of Concept Trial Planned for Kenya, India and South Africa ROCKVILLE, Md., Oct. 10, 2012 /PRNewswire-USNewswire/ -- Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01(E)(*) adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and...